Venous diseases treatment market is set to reach US$ 11.63 billion by 2032, North America leads the market with 40% market share.

The global venous diseases treatment market size was valued at USD 6.62 billion in 2024 and is expected to reach USD 11.63 billion by 2032, at a CAGR of 7.30% during the forecast period

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/venous-diseases-treatment-market?prtk

United States: Key Industry Developments

✅ January 2026: U.S. varicose vein treatment market reached USD 549.6 million valuation, driven by minimally invasive procedures comprising 70% share and expanding outpatient access in Medicare-covered regions.​

✅ December 2025: Boston Scientific expanded VenaSeal closure system indications for superficial vein treatments, reducing procedure times by 25% for chronic venous insufficiency management.

✅ September 2025: Medtronic launched next-gen radiofrequency ablation catheter for endovenous procedures, featuring AI-guided energy delivery to improve closure rates above 95%.

Asia Pacific / Japan: Key Industry Developments

✅ May 2025: Chugai Pharmaceutical obtained MHLW approval for Vabysmo in choroidal neovascularization from angioid streaks, Japan's first treatment for this vascular eye disease linked to venous pathology.

✅ December 2025: Takeda advanced venous thromboembolism programs with Phase III data presentations, targeting novel anticoagulants for high-risk Japanese patients post-surgery.

✅ October 2025: Japanese Society of Phlebology endorsed ultrasound-guided foam sclerotherapy protocols, standardizing minimally invasive varicose vein treatments nationwide.

Recent M&A activities:-

→ In January 15, 2026, Boston Scientific agreed to acquire Penumbra, Inc. in a $14.5 billion deal to significantly expand its cardiovascular and vascular device portfolio, including products relevant to venous thromboembolism and deep vein thrombosis treatments. The acquisition adds Penumbra's cardiovascular devices (including pulmonary embolism and DVT‐related products) to Boston Scientific's offerings and is expected to close in 2026.

→ On February 19, 2025, Stryker completed the acquisition of Inari Medical, Inc. for approximately $4.9 billion in cash. This strategic deal enhances Stryker's portfolio in venous thromboembolism and peripheral vascular device solutions used in the treatment of deep vein thrombosis and pulmonary embolism by bringing Inari's thrombectomy systems into Stryker's vascular device lineup.

Key Players:-
Biolitec AG Untere Viaduktgasse, Teleflex Incorporated, BD, B. Braun Melsungen Ag, Alma Lasers, Becton Dickinson and Company, Koninklijke Philips N.V.

Top 5 Key Players Analysis:-

Biolitec AG - A specialist in advanced laser‐based ablation technologies for varicose and chronic venous disease, Biolitec holds a strong niche position particularly in Europe and is recognized for precision fiber systems.

Teleflex Incorporated - A US‐based medical device manufacturer with broad vascular intervention products, Teleflex captures notable share in radiofrequency and closure device segments and leverages global hospital distribution.

BD (Becton, Dickinson and Company) - BD contributes to the market through venous access, ablation systems and RF technologies and expanded its reach with acquisitions (e.g., Venclose), boosting its procedural solution share.

B. Braun Melsungen AG - As a major global medical tech and device company, B. Braun's extensive portfolio in vascular and surgical products helps it maintain a meaningful portion of the treatment device revenue worldwide.

Koninklijke Philips N.V. - Philips holds share in the venous disease market with diagnostic imaging and venous stent/closure systems, and recent product launches (such as advanced venous stents) reinforce its competitive stance globally.

Tech & Strategic Partnerships:-

1. Major Acquisition Bolstering Venous Technology Portfolio
• Stryker acquires Inari Medical - In early 2025, Stryker completed the acquisition of Inari Medical, Inc., a specialist in venous thromboembolism (VTE) devices, strengthening its foothold in peripheral vascular and venous treatments and expanding its innovative device portfolio tailored to venous clot removal without thrombolytics.

2. Digital Health Collaboration in Vein Care
• Boston Scientific partners with a telehealth provider - In 2025, Boston Scientific entered a partnership to integrate remote patient monitoring and digital follow‐up into its varicose vein treatment ecosystem, reflecting the trend toward connected care and improved patient engagement.

3. Device Innovation & Market Expansion
• Medtronic launches advanced devices and expands regional partnerships - Medtronic introduced new minimally invasive varicose vein treatment devices in 2025 and expanded partnerships, including growth initiatives in India, to scale adoption of modern vascular treatments.

4. Innovative Clinical Trial Progress Highlighting Emerging Tech
• High‐Intensity Focused Ultrasound in varicose vein care - Theraclion progressed clinical work on its SONOVEIN® ultrasound platform with new treatment speed enhancements in early 2025, showcasing alternative non‐thermal technologies for venous disorders.

5. Certification & Distribution Partnerships for Next‐Gen Platforms
• VVT Medical's regulatory and market entry deals - VVT secured key certifications (FDA & CE) and distribution arrangements for its non‐thermal, anesthesia‐free venous treatment systems, enabling broader access to innovative minimally invasive procedures.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=venous-diseases-treatment-market?prtk

Market Drivers :-

Increasing cases of varicose veins, chronic venous insufficiency (CVI), and deep vein thrombosis (DVT) are expanding addressable demand globally. For example, CVI prevalence reached 45.6% in adults in some studies, highlighting a large untreated population base.

Growing obesity and sedentary lifestyles further fuel incidence rates, driving demand for therapeutics and procedures.

Age‐associated decline in vascular health increases the risk and severity of venous disorders, especially in developed markets, creating sustained long‐term growth.

Healthcare systems are prioritizing screening and treatment due to growing elderly patient pools.

Adoption of endovenous procedures (e.g., radiofrequency ablation, endovenous laser therapy, foam sclerotherapy) is rising due to faster recovery, better outcomes, and reduced complications.

Innovation in ablation devices and imaging guidance is enhancing physician confidence and patient acceptance.

Increased public and clinician awareness about venous disease symptoms and available treatments encourages earlier intervention, boosting market penetration.

Education campaigns and screening programs in both developed and emerging economies are accelerating diagnosis rates.

Growing preference for outpatient procedures and aesthetic‐focused treatments (e.g., laser therapy for varicose veins) is broadening patient segments beyond strictly clinical necessity.

Regional Insights:-
North America
North America holds the largest share in the venous diseases treatment market at approximately 40%, led by the U.S. with advanced healthcare infrastructure, high procedural adoption, and significant investment in minimally invasive treatments.
Strong patient awareness and robust reimbursement systems further support sustained market dominance.

Europe
Europe accounts for around 29% of the global market, driven by established public healthcare systems and widespread clinical adoption of venous therapies in countries like Germany, France, and the UK.
Government initiatives and high standards of vascular care support steady market growth.

Asia‐Pacific
Asia‐Pacific contributes roughly 34% of the global venous diseases treatment market, with rapid expansion thanks to rising healthcare access, growing awareness of venous disorders, and increasing outpatient procedures.
China leads within the region, while India is expected to register the highest growth rate due to expanding specialty care and increasing health awareness.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/venous-diseases-treatment-market?prtk

Market Segmentation

By Treatment Type: Includes Surgeries, Sclerotherapy, Angioplasty/Stenting, Vein Ligation & Stripping, Vena Cava Filter, Ambulatory Phlebectomy, Radiofrequency Ablation, Laser Treatment, and other therapies.

By Disease Type: Covers Deep-vein Thrombophlebitis, Varicose & Spider Veins, Superficial Thrombophlebitis, Chronic Venous Insufficiency, Venous Ulcers, and other venous conditions.

By Product Type: Comprises Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injections, and other related products.

By End User: Targets Hospitals, Ambulatory Centers, and other healthcare facilities.

By Distribution Channel: Includes Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and other distribution methods.

FAQ'S:-

Q1: What are the common treatments for venous diseases?
A1: Treatments include compression therapy, medications, minimally invasive procedures, and surgeries to improve blood flow.

Q2: Which patients are most likely to need venous disease treatments?
A2: Individuals with varicose veins, chronic venous insufficiency, or deep vein thrombosis are the primary candidates.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.